newsfilter
← Latest News
GlobeNewswire·

Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS) ("Alumis" or the "Company"), a clinical stage biopharmaceutical company developing oral therapies using a precision approach to